Immunomodulatory drugs

Cancer Investigation

Volumn 23, Issue 7, 2005, Pages 625-634

  Crane, Edward ^b   List, Alan ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Actimid; Angiogenesis; Anti angiogenesis; CC 4047; CC 5013; IMiD; Immunomodulatory drug; Interleukin 12; Lenalidomide; Mantle cell lymphoma; Melanoma; Myelodysplastic syndrome; REVLIMID; Thalidomide; Tumor necrosis factor alpha; Waldenstrom's macroglobulinemia

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; RECEPTOR BLOCKING AGENT; RITUXIMAB; TEMOZOLOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; WARFARIN;

ANGIOGENESIS; BIRTH DEFECT; BRAIN METASTASIS; BREAST CANCER; CANCER CONTROL; CANCER REGRESSION; CANCER SURVIVAL; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; CONSTIPATION; CYTOKINE PRODUCTION; CYTOLYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; EAR MALFORMATION; EFFECTOR CELL; EYE MALFORMATION; GASTROINTESTINAL MALFORMATION; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPOTENTIATION; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOCOMELIA; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; SEDATION; SIDE EFFECT; SOMNOLENCE; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TUMOR GROWTH; WALDENSTROEM MACROGLOBULINEMIA;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-12; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES; THALIDOMIDE;

EID: 33344475032     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357900500283101     Document Type: Review

References (65)

1. Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 1965, 40 (6), 303-306.
2. Waters, M.F. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr. Rev. 1971, 42 (1), 26-42.
3. Pearson, J.M.; Vedagiri, M. Treatment of moderately severe erythema nodosum leprosum with thalidomide - a double-blind controlled trial. Lepr. Rev. 1969, 40 (2), 111-116.
4. Fabbri, P.; Cardinali, C.; Giomi, B.; Caproni, M. Cutaneous lupus erythematosus: diagnosis and management. Am. J. Clin. Dermatol. 2003, 4 (7), 449-465.
5. Goker, B.; Goker, H. Current therapy for Behcet's disease. Am. J. Ther. 2002, 9 (5), 465-470.
6. Davey, P.P.; Ashrafian, H. New therapies for heart failure: is thalidomide the answer? QJM 2000, 93 (5), 305-311.
7. Bartlett, J.B.; Dredge, K.; Dalgleish, A.G. The evolution of thalidomide and its IMID derivatives as anticancer agents. Nat. Rev., Cancer 2004, 4 (4), 314-344.
8. Moreira, A.L.; Sampaio, E.P.; Zmuidzinas, A.; Frindt, P.; Smith, K.A.; Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 1993, 6 (177), 1675-1680.
9. Keifer, J.A.; Guttridge, D.C.; Ashburner, B.P.; Baldwin, A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of NFkappaB kinase activity. J. Biol. Chem. 2001, 276 (25), 22382-22387.
10. Sampaio, E.P.; Kaplan, G.; Miranda, A.; Nery, J.A.; Miguel, C.P.; Viana, S.M.; Sarno, E.N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 1993, 168 (2), 408-414.
11. Muller, G.W.; Corral, L.G.; Shire, M.G.; Wang, H.; Moreira, A.; Kaplan, G.; Stirling, D.I. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J. Med. Chem. 1996, 39 (17), 3238-3240.
12. Muller, G.W.; Shire, M.G.; Wong, L.M.; Corral, L.G.; Patterson, R.T.; Chen, Y.; Stirling, D.I. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg. Med. Chem. Lett. 1999, 9 (11), 1625-1630.
13. Marriott, J.B.; Clarke, I.A.; Dredge, K.; Muller, G.; Stirling, D.; Dalgleish, A.G. Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clin. Exp. Immunol. 2002, 130 (1), 75-84.
14. Wolkenstein, P.; Latarjet, J.; Roujeau, J.C.; Duguet, C.; Boudeau, S.; Vaillant, L.; Maignan, M.; Schuhmacher, M.H.; Milpied, B.; Pilorget, A.; Bocquet, H.; Brun-Buisson, C.; Revuz, J. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998, 352 (9140), 1586-1589.
15. Bartlett, J.B.; Michael, A.; Clarke, I.A.; Dredge, K.; Nicholson, S.; Kristeleit, H.; Polychronis, A.; Pandha, H.; Muller, G.W.; Stirling, D.I.; Zeldis, J.; Dalgleish, A.G. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer 2004, 90 (5), 955-961.
16. Corral, L.G.; Haslett, P.A.; Muller, G.W.; Chen, R.; Wong, L.M.; Ocampo, C.J.; Patterson, R.T.; Stirling, D.I.; Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs which are potent inhibitors of TNF-alpha. J. Immunol. 1999, 163 (1), 380-386.
17. Haslett, P.A.; Klausner, J.D.; Makonkawkeyoon, S.; Moreira, A.; Metatratip, P.; Boyle, B.; Kunachiwa, W.; Maneekam, N.; Vongchan, P.; Corral, L.G.; Elbeik, T.; Shen, Z.; Kaplan, G. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res. Hum. Retrovir. 1999, 15 (130), 1169-1179.
18. Trinchieri, G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 1998, 70, 83-243.
19. Gavallo, F.; Carlo, E.D.; Quaglin, E.; Jezzi, M.; Strasly, M.; Bussolino, F.; Colombo, M.P.; Nanni, P.; Lollini, P.L.; Musiani, P.; Forni, G. Prevention by delay: nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice. J. Biol. Regul. Homeost. Agents 2001, 15 (4), 351-358.
20. Gupta, D.; Treon, S.P.; Shima, Y.; Hideshima, T.; Podar, K.; Tai, Y.T.; Lin, B.; Lentzsch, S.; Davies, F.E.; Chouhan, D.; Schlossman, R.L.; Richardson, P.; Ralph, P.; Wu, L.; Payvandi, F.; Muller, G.; Stirling, D.I.; Anderson, K.C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic implications. Leukemia 2001, 15 (12), 1950-1961.
21. Lentzsch, S.; LeBlanc, R.; Podar, K.; Dabies, F.; Lin, B.; Hideshima, T.; Catley, L.; Stirling, D.I.; Anderson, K.C. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells an angiogenesis in vivo. Leukemia 2003, 17 (1), 41-44.
22. Dredge, K.; Marriott, J.B.; Macdonald, C.D.; Man, H.-W.; Chen, R.; Muller, G.W.; Stirling, D.; Dalgleish, A.G. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer 2002, 87 (10), 1166-1172.
23. Mueller, D.L.; Jenkins, M.K.; Schwartz, R.H. Clonal expansion versus functional clonal inactivation: a co-stimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 1989, 7, 445-480.
24. Haslett, P.A.J.; Corral, L.G.; Albert, M.; Kaplan, G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J. Exp. Med. 1998, 187 (11), 1885-1892.
25. Haslett, P.A.J.; Hanekom, W.A.; Muller, G.; Kaplan, G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J. Infect. Dis. 2003, 187 (6), 946-955.
26. Dredge, K.; Marriott, J.B.; Todryk, S.M.; Muller, G.W.; Chen, R.; Stirling, D.I.; Dalgleish, A.G. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 2002, 168 (10), 4914-4919.
27. Zeldis, J.B.; Williams, B.A.; Thomas, S.D.; Elsayed, M.E. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. 1999, 21 (2), 319-330.
28. Kumar, S.; Witzig, T.E.; Rajkumar, S.V. Thalidomide: current role in the treatment of non-plasma cell malignancies. J. Clin. Oncol. 2004, 22 (12), 2477-2488.
29. Weber, D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 2003, 10 (5), 375-383.
30. Zangari, M.; Barlogie, B.; Anaissie, E.; Saghafifar, F.; Eddlemon, P.; Jacobson, J.; Lee, C.-K.; Thertulien, R.; Talamo, G.; Thomas, T.; Van Rhee, F.; Fassas, A.; Fink, L.; Tricot, G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. BJH 2004, 126 (5), 715-721.
31. Richardson, P.G.; Schlossman, R.L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F.; LeBlanc, R.; Catley, L.P.; Doss, D.; Kelly, K.; McKenney, M.; Mechlowicz, J.; Freeman, A.; Deocampo, R.; Rich, R.; Ryoo, J.J.; Chauhan, D.; Balinski, K.; Zeldis, J.; Anderson, K.C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100 (9), 3063-3067.
32. Schey, S.A.; Fields, P.; Bartlett, J.B.; Clarke, I.A.; Ashan, G.; Knight, R.D.; Streetly, M.; Dalgleish, A.G. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 2004, 22 (16), 3269-3276.
33. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999, 341 (21), 1565-1571.
34. Barlogie, B.; Desikan, R.; Eddlemon, P.; Spencer, T.; Zeldis, J.; Munshi, N.; Badros, A.; Zangari, M.; Anaissie, E.; Epstein, J.; Shaughnessy, J.; Ayers, D.; Spoon, D.; Tricot, G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98 (2), 492-494.
35. Yakoub-Agha, I.; Attal, M.; Dumontet, C.; Delannoy, V.; Moreau, P.; Berthou, C.; Lamy, T.; Growbois, B.; Dauriac, D.; Dorvaux, V.; Bay, J.O.; Monconduit, M.; Harousseau, J.L.; Duguet, C.; Duhamel, A.; Facon, T. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the intergroupe francophone du myélome (IFM). Hematol. J. 2002, 3 (4), 185-192.
36. Schey, S.A.; Cavenagh, J.; Johnson, R.; Child, J.A.; Oakervee, H.; Jones, R.W. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk. Res. 2003, 27 (10), 909-914.
37. Tosi, P.; Zamagni, E.; Cellini, C.; Ronconi, S.; Patriarca, F.; Ballerini, F.; Musto, R.; Di Raimondo, F.; Ledda, A.; Lauria, F.; Masini, L.; Gobbi, M.; Vacca, A.; Ria, R.; Cangini, D.; Tura, S.; Baccarani, M.; Cavo, M. Salvage therapy with thalidomide in patients with advanced relapsed/ refractory multiple myeloma. Haematologica 2002, 87 (4), 408-414.
38. Hus, M.; Dimoszynska, A.; Soroka-Wojtaszko, M.; Jawniak, D.; Legiec, W.; Ciepnuch, H.; Hellmann, A.; Wolska-Smolen, T.; Skotnicki, A.; Manko, J.; for the Polish Multiple Myeloma Study Group Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001, 86 (4), 404-408.
39. Hideshima, T.; Chauhan, D.; Shima, T.; Raje, N.; Davies, R.E.; Tai, Y.T.; Treon, S.P.; Lin, B.; Schlossman, R.L.; Richardson, R.; Muller, G.; Stirling, D.I.; Anderson, K.C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional chemotherapy. Blood 2000, 96 (9), 2943-2950.
40. Kumar,S.;Gertz,M.A.;Dispenzieri,A.;Lacy,M.Q.;Geyer,S.M.;Iturria,Iturria, Iturria, N.L.; Fonseca, R.; Hayman, S.R.; Lust, J.A.; Kyle, R.A.; Greipp, P.R.; Witzig, T.E.; Rajkumar, S.V. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin. Proc. 2003, 78 (1), 34-39.
41. Dimopoulos, M.A.; Zervas, K.; Kouvatseas, G.; Galani, E.; Grigoraki, V.; Kiamouris, C.; Vervessou, E.; Samantas, E.; Papadimitriou, C.; Economou, O.; Gika, D.; Panayiotidis, P.; Christakis, I.; Anagnostopoulos, N. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. 2001, 12 (7), 991-995.
42. Weber, D.; Rankin, K.; Gavino, M.; Delasalle, K.; Alexanian, R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 2003, 21 (1), 16-19.
43. Anagnostopoulos, A.; Weber, D.; Rankin, K.; Delasalle, K.; Alexanian, R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. 2003, 121 (5), 768-771.
44. Garcia-Sanz, R.; Gonzalez-Porras, J.R.; Hernandez, J.M.; Polo-Zarzuela, M.; Sureda, A.; Barrenetxea, C.; Palomera, L.; Lopez, R.; Grande-Garcia, C.; Alegre, A.; Vargas-Pabon, M.; Gutierrez, O.N.; Rodriguez, J.A.; San Miguel, J.F. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/ refractory multiple myeloma. Leukemia 2004, 18 (4), 856-863.
45. Srkalovic, G.; Elson, P.; Trebisky, B.; Karam, M.A.; Hussein, M.A. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med. Oncol. 2002, 19 (4), 219-226.
46. Dimopoulos, M.A.; Zomas, A.; Viniou, N.A.; Grigoraki, V.; Galani, E.; Matsouka, C.; Economou, O.; Anagnostopoulos, N.; Panayiotidis, P. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J. Clin. Oncol. 2001, 19 (6), 3596-3601.
47. Coleman, M.; Leonard, J.; Lyons, L.; Szelenyi, H.; Niesvizky, R. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin. Oncol. 2003, 30 (2), 270-274.
48. Dimopoulos, M.A.; Tsatalas, C.; Zomas, A.; Hamilos, G.; Panayiotidis, P.; Margaritis, D.; Matsouka, C.; Economopoulos, T.; Anagnostopoulos, N. Treatment of Waldenstrom's macroglobulinemia with single agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin. Oncol. 2003 (30), 265-269.
49. Mitsiades, C.S.; Mitsiades, M.; McMullan, C.J.; Poulaki, B.; Hideshima, T.; Chauhan, D.; Treon, S.P.; Rishardson, P.G.; Munshi, N.C.; Joseph, M. Immunomodulatory thalidomide derivatives have activity against tumor cells from Waldenstrom's macroglobulimemia. Blood 2003, 102 (11), 3360 (Abstr.).
50. Hernandez-Ilizaliturri, F.J.; Reddy, N.; Holkova, B.; Czuczman, M.S. Addition of immunomodulatory drugs CC5013 or CC4047 to rituximab enhances anti-tumor activity in severe combined immunodeficiency mouse lymphoma model. Clin. Cancer Res. 2005, 11 (16), 5984-5992.
51. Kaufmann, H.; Raderer, M.; Wöhrer, S.; Püspök, A.; Bankier, A.; Zielinski, C.; Chott, A.; Drach, J. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004, 104 (8), 2269-2271.
52. Eisen, T.; Boshoff, C.; Mak, I.; Sapunar, F.; Vaughan, M.M.; Pyle, L.; Johnston, S.R.; Ahern, R.; Smith, I.E.; Gore, M.E. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer 2000, 82 (4), 812-817.
53. Reiriz, A.B.; Richter, M.; Fernandes, S.; Cancela, A.; Dalla Costa, T.; Di Leone, L.; Schwartsmann, G. A phase II study of thalidomide in patients with metastatic malignant melanoma. Proc. Am. Soc. Clin. Oncol. 2003, 22 (720), 2895 (Abstr.).
54. Hwu, W.J.; Krown, S.E.; Menell, J.H.; Panageas, K.S.; Merrell, J.; Lamb, L.A.; Williams, L.J.; Quinn, C.J.; Foster, T.; Chapman, P.B.; Livingston, P.O.; Wolchok, J.D.; Houghton, A.N. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 2003, 21, 3351-3356.
55. Danson, S.; Lorigan, P.; Arance, A.; Clamp, A.; Ranson, M.; Hodgetts, J.; Lomax, L.; Ashcroft, L.; Thatcher, N.; Middleton, M.R. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol. 2003, 21 (13), 2551-2557.
56. Raza, A.; Meyer, P.; Dutt, D.; Zorat, F.; Lisak, L.; Nascimben, F.; du Randt, M.; Kapar, D.; Goldberg, C.; Loew, J.; Dar, S.; Gezer, S.; Venugopal, P.; Zeldis, J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98 (4), 958-965.
57. Zorat, F.; Shetty, V.; Dutt, D.; Lisak, L.; Nascimben, F.; Allampallam, K.; Dar, S.; York, A.; Gezer, S.; Venugopal, P.; Raza, A. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. J. Haematol. 2001, 115 (4), 881-894.
58. Strapp, C.; Germing, U.; Aivado, M.; Misgeld, F.; Hass, R.; Gattermann, N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002, 16 (1), 1-6.
59. List, A.F.; Kurtin, S.; Roe, D.J.; Buresh, A.; Mahadevan, D.; Fuchs, D.; Rimsza, L.; Heaton, R.; Knight, R.D.; Zeldis, J.B. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 2005, 352 (6), 549-557.
60. Streetly, M.; Gyertson, K.; Kazmi, M.; Zeldis, J.; Schey, S.A. Alternate day actimid (CC-4047) is well tolerated and is active when used to treat relapsed/refractory myeloma. ASH Proc. 2004, 332 (Abstr.).
61. Barlogi, B.; Shaughnessy, J.; Tricot, G.; Jacobson, J.; Zangari, M.; Anaissie, E.; Walker, R.; Crowley, J. Treatment of multiple myeloma. Blood 2004, 103 (1), 20-32.
62. Rajkumar, S.V.; Hayman, S.R.; Lacy, M.Q.; Dispenzieri, A.; Hoering, A.; Geyer, S.M.; Zeldenrust, S.R.; Greipp, P.R.; Fonseca, R.; Lust, J.A.; Russell, S.J.; Kyle, R.A.; Witzig, T.E.; Gertz, M.A. Combination therapy with CC-5013 (Lenalidomide; Revlimid) plus dexamethasone (Rev/Dex) for newly diagnosed multiple myeloma. ASH Proc. 2004, 331 (Abstr.).
63. Liu, Y.; Yohnya, T.M.; Figg, W.D.; Gulley, J.L.; Arlen, P.M.; Parker, C.; Fedenko, K.; Chen, C.C.; Jones, E.; Dahut, W.L. Phase I study of CC-5013 (Revimid), a thalidomide derivative in patients with refractory metastatic cancer. Proc. Am. Soc. Clin. Oncol. 2003, 927 (Abstr.).
64. Amato, R.J.; Floissac, M.; Knight, R.; Levin, A.; Glode, M.; Crawford, D. Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPC). Prostate Cancer Symp. 2005, 252 (Abstr.).
65. Chapa, P.; Rawat, A.; Amato, R.J. Phase II study of CC-5013 in patients (pts) with renal cell cancer (RCC). ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004, 22 (14S), 4761 (Abstr.).